- There are no upcoming events available at this time.
. Christos Mantzoros, MD, MSC, director of the Human Nutrition Unit in the Division of Endocrinology, Diabetes, and Metabolism at BIDMC, and the first scientist to document the role of the hormone leptin in regulating the body’s response to hunger in humans, accepted the Obesity Society’s 2017 TOPS Research Achievement Award on November 1. The most prestigious award given by the Obesity Society – which publishes the journal Obesity, the world’s leading peer-reviewed obesity research journal – recognizes an individual for singular achievement or contribution to research in the field. “Metabolic diseases – obesity, diabetes and associated ailments such as cardiovascular diseases, strokes and some kinds of cancer – are the epidemics of the 21st century,” said Mantzoros. “Our group works hard to understand the mechanisms underlying these disorders, to prevent, diagnose and treat these disease states by developing novel diagnostic and therapeutic tools for these conditions.”
. To repair ruptured or pierced organs and tissues, surgeons commonly use staples, sutures and wires to bring and hold the wound edges together so that they can heal. However, these procedures can be difficult to perform in hard-to-reach areas of the body and wounds are often not completely sealed immediately. Recently published in Science Translational Medicine, a study presents a robust solution for the efficient repair of wounds in mechanically challenging body areas. Sidhu Gangadharan, MD, Chief of Thoracic Surgery and Interventional Pulmonology at BIDMC, collaborated with other researchers to demonstrate that a sealant, based on elastin—a human, resilience-imparting protein present in all elastic tissues such as the wall of arteries, skin, and lungs—can be photochemically tuned to effectively seal incisions in arteries and lungs of rats and to repair wounds in the lungs of pigs, all suture and staple-free.
. BIDMC-TVO is pleased to announce Pfizer’s Centers for Therapeutic Innovation (CTI) Fall 2017 call for pre-proposals with submission deadline: Friday, October 13, 2017. The Pfizer CTI program collaborates with leading academic medical centers, the NIH and foundations to speed the translation of novel targets into potential therapeutics. Pfizer offers access to its drug development capabilities and lab facilities for these BIDMC-CTI collaborations. BIDMC Researchers working on large or small molecules for therapeutics in the areas of oncology, inflammation & immunology, cardiovascular & metabolic diseases, neuroscience and rare diseases should apply. Informational office hours will be held on: Tuesday, October 3, 2017, 10am - 5pm at CLS, 18th Floor, Room 1810A, 3 Blackfan Circle, Boston. To schedule a 20 minutes meeting with Nader Halim, PhD (External Science & Innovation, Pfizer) regarding the CTI call for pre-proposals, please e-mail Cindy Wong: email@example.com.
. On Tuesday, October 31 from 12-2 PM, the HMS Initiative for RNA Medicine and the BIDMC Technology Ventures Office will co-host a lunchtime panel discussion in the Pechet Room at the Joseph B. Martin Conference Center. Speakers: Sudhir Agrawal, DPhil; Jeannie T. Lee, MD, PhD; Jason Rhodes, MBA. Moderators: Frank Slack, PhD; Wanni A. Davis, PhD, MBA.